Search for: "In re Eli F. (1989)"
Results 21 - 40
of 44
Sorted by Relevance
|
Sort by Date
24 Feb 2011, 1:49 pm
Aug. 2, 1999); In re Rezulin Products Liability Litigation, 133 F. [read post]
13 Nov 2014, 5:00 am
Eli Lilly & Co., ___ F. [read post]
1 Feb 2007, 6:07 am
Minn. 1989). [read post]
8 Oct 2015, 5:00 am
Eli Lilly & Co., 58 F. [read post]
13 Apr 2010, 10:26 am
Eli Lilly & Co., No. 2008-1248, 2010 WL 1007369 (Fed. [read post]
20 Mar 2009, 2:05 am
United States, 880 F.2d 84, 86-87 (8th Cir. 1989).Kansas: Savina v. [read post]
3 Feb 2011, 2:11 pm
Pa. 1989) (citation and quotation marks omitted), aff’d mem., 902 F.2d 1558 (3d Cir. 1989); accord Keath v. [read post]
12 Jun 2023, 1:09 pm
., 563 F. 3d 171, 178 (6th Cir 2009); Westberry v. [read post]
26 May 2015, 7:42 am
So far many plaintiffs have had trouble coming up with factual support to back such allegations – and sometimes we’re not even sure why they’re making them. [read post]
6 Oct 2011, 4:37 pm
Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. [read post]
25 Sep 2017, 7:22 pm
Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. [read post]
25 Sep 2017, 7:22 pm
Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. [read post]
16 Aug 2007, 7:20 am
Hess, 536 N.E.2d 1126, 1135 (N.Y. 1989) ("a plaintiff waives the physician-patient privilege by commencing an action which puts plaintiff's own physical condition in issue"); Nelson v. [read post]
18 Feb 2010, 10:34 am
But some fraud on the FDA claims can’t be “preempted” because they’re not subject to the Supremacy Clause from which the preemption doctrine flows. [read post]
27 Aug 2023, 3:56 pm
On August 14, 2023, a Fulton County, Georgia grand jury returned a 41-count indictment against former President Donald Trump and eighteen other individuals for a conspiracy to overturn the legitimate 2020 presidential election results in that state. [read post]
18 Dec 2008, 10:36 pm
Eli Lilly & Co., 99 F.R.D. 126, 128 (D.D.C. 1983)). [read post]
9 Apr 2015, 5:00 am
Eli Lilly & Co., 503 F. [read post]
9 Jan 2024, 12:05 pm
In re Abbott, 954 f.3d 772 (5th Cir. 2020), vacated, 141 S. [read post]
4 Mar 2012, 9:02 am
Merrill Dow Pharmaceuticals, Inc., 874 F.2d 307, 311-12 (5th Cir. 1989)(“Fortunately, we do not have to resolve any of the above questions [as to bias and confounding], since the studies presented to us incorporate the possibility of these factors by the use of a confidence interval. [read post]
10 Feb 2023, 4:44 am
Putting aside the idiosyncratic chapter by the late Professor Berger, most of the third edition of the Reference Manual presented guidance on many important issues. [read post]
